Upload
peregrine-cain
View
215
Download
1
Tags:
Embed Size (px)
Citation preview
Development of Advanced Adjuvants Development of Advanced Adjuvants and Immune Modulatorsand Immune Modulators
R.E.W. (Bob) Hancock,Centre for Microbial Diseases and
Immunity Research,University of British Columbia
0
10
20
30
40
50
60
70
80
90
100
0 1 2 3 4 5 6 7 8 9 10 11 12 13
% S
urvi
val
Days post-infection
Therapeutic IDR-1018 + Anti-malarial
Anti-malarial Control Peptide
No Treatment
10 6 PbA
d 04 days (Par 3-6%)
1018 or IDR-1d 4, 5, 6
Pyrimethamine + Chloroquine indrinking water
p = 0.034
0
10,000
20,000
30,000
40,000
Day 0 Day 22
Immunize
Important host defense mechanism in all complex species of life.
>1000 peptides known. Diverse amino acid sequences and structures.
12 to 40 (or more) amino acids. Net charge +2 to +9 (Lys; Arg). Amphipathic.
Role in Innate Immunity involves antimicrobial, immunomodulatory and anti-biofilm activities; “Host Defence” peptides.
Modulate Innate & Adaptive Immunity
Cationic PeptidesCationic PeptidesBirds do it, bees do it, even educated fleas do it.... Cole Porter
New immunomodulatory peptides show New immunomodulatory peptides show broad protection in Mouse Model Infectionsbroad protection in Mouse Model Infections
Lars Steinstraesser, Louis Schofield, Ariel Achtman, Bruno Rivas, Rogelio Hernandez Pando, Carina Mallard
Also protects vs. E. coli, Salmonella, Klebsiella, Pseudomonas, MRSA,
VRE, Pox & HSV viruses
IBD, CF, Sterile inflammation; LPS/hypoxia-ischemia
Wound Healing
IDR 1018: IDR 1018: VRLIVAVRIWRR-NHVRLIVAVRIWRR-NH22
Balb/c mice infected IT with high dose 106
virulent live MTb strain H37Rv .
After 2 months of infection, treatment via IT: 32 g (~1 mg/kg) peptides every 2 days.
Groups of 5 animals sacrificed after 4 wks of treatment and lung bacilli counted.
Works vs. H37Rv &MDR TBstrains.
Bruno Rivas and Rogelio Hernandez Pando, UNA de México
0
10
20
30
40
50
60
70
80
90
100
0 1 2 3 4 5 6 7 8 9 10 11 12 13
% S
urvi
val
Days post-infection
Therapeutic IDR-1018 + Anti-malarial
Anti-malarial Control Peptide
No Treatment
10 6 PbA
d 04 days (Par 3-6%)
1018 or IDR-1d 4, 5, 6
Pyrimethamine + Chloroquine indrinking water
p = 0.034
MDR -TB Mouse Model Cerebral Malaria Mouse ModelInvasive Staph. aureus Mouse Model
Science Transl. Med. 4:135ra64, 2012
Science Transl. Med. 4:135ra64, 2012
PLoS One 8:e59119, 2013
● PBS■ IDR-1018
In mice& pigs
Time (days)
PLoS One 7:e39373, 2012
Intranasal delivery (Single dose)Intranasal delivery (Single dose)Pseudomonas aeruginosaPseudomonas aeruginosa lung infections lung infections
0
2
4
6
8
Lo
g1
0 C
FU
/ml
* (p = 0.017)
Wat
er
1002
(1 m
g/kg)
1002
(2 m
g/kg)
1002
(4 m
g/kg)
0
20
40
60
80
100
TN
Fa
(pg
/ml)
in B
AL
F
Protective Protective Immunity Immunity
Harmful Harmful Inflammation Inflammation
Peptides work by stimulating protective immunity while suppressing potentially harmful inflammation
Adjuvants and ImmunityAdjuvants and ImmunityAdaptive immunity is antigen-specific, requires gene
rearrangements and thus is slow to develop (days to weeks) and
can discriminate between self and non self. Exploited with Vaccines
Innate immunity fast acting and relatively non-specific. Exploited using immune modulators and adjuvants
But “Innate immunity instructs adaptive immunity” & effectors
overlap
Mechanisms still not well understood but:
Adjuvants can either Act as a depot (focus) Recruit Immune cells Activate Immune Cells
Node
Interaction
TLR4 to NFTLR4 to NFB interactomeB interactome
Need for affordable adjuvantsNeed for affordable adjuvants
Adjuvant platform should cost pennies per dose!
Vaccination Site Vaccination Site Ivory CoastIvory Coast
Roadblocks to Effective VaccinesRoadblocks to Effective Vaccines
Volker Gerdts, Lorne Babiuk, Bob Hancock and many others
Need for multiple dosing (e.g. 3-5 doses for DPT); Reduces compliance; Delays protection.
Maternal interference
Current adjuvants like Alum are biased to Th2 responses
Neonates respond poorly
New prime boost regimens show only partial protection
Triple adjuvant combination gives the potential Triple adjuvant combination gives the potential for single dose protection vs. pertussisfor single dose protection vs. pertussis
PTd (pertussis toxoid alone)PTd & HH2
PTd & PPPTd & PP & CpG-C
PTd & CpG-C
PTd & PP & CpG-C & HH2PTd & PP & CpG-C & HH2
PTd & PP & CpG-C & HH2PTd & PP & CpG-C & HH2
CpG ODNIDR
PeptidePolyphosphazene; PP
0
10,000
20,000
30,000
40,000
Day 0 Day 22
Immunize
Ptd = pertussis toxoide.g. Vaccine 31:3148-55, 2013
Also works with RSV, Flu, Chlamydia prime-boost
High TitreMixed Th1, Th2
Single DoseProtective
Pigs, Cattle, MiceWorks in Neonates
Long duration
ActivateActivate DepotDepotRecruitRecruit
Mouse doseMouse dose0.6 0.6 g CpG, 1.2 g CpG, 1.2 g g
HDP, 0.6 HDP, 0.6 g g PolyphosphazenePolyphosphazene
Antigen SparingAntigen Sparing
Duration of immunity > 2 years Duration of immunity > 2 years (mice)(mice)
>10 months in pigs>10 months in pigs
Comparison to Alum (2 different Comparison to Alum (2 different doses)doses)
2 4 6 8 10 12 14 16 191.0×102
1.0×103
1.0×104
1.0×105
1.0×106
*
*
Weeks
IgG
2a A
nti
bo
dy
Tit
re
2 4 81
21
61
92
22
63
03
4 3
84
25
26
16
87
68
59
0
1.0×101
1.0×102
1.0×103
1.0×104
1.0×105
1.0×106
Weeks
IgG
2a A
nti
bo
dy
Tit
re
Bacterial burden day 2
0
50000
100000
150000
200000
250000
cfu
per
tota
l lu
ng
lesio
n
**
Features of the Adjuvant FormulationFeatures of the Adjuvant Formulation
Protective – Neonatal pigsProtective – Neonatal pigs Works mucosally at very low dosesWorks mucosally at very low doses
VaccinationOVA plus 0.6 g CpG, 1.2 g HDP, 0.6 g Polyphosphazene
AcknowledgementsAcknowledgementsLab: Ana Nijnik, Neeloffer Lab: Ana Nijnik, Neeloffer Mookherjee, Evan Haney, Mookherjee, Evan Haney,
Ashley Hilchie, Kelli Wuerth, Ashley Hilchie, Kelli Wuerth, Melisssa Elliott, IDR peptide Melisssa Elliott, IDR peptide Team; Bioinformatics Team Team; Bioinformatics Team
Collaborators: Volker Gerdts, VIDO crew, Scott Halperin, Jun Collaborators: Volker Gerdts, VIDO crew, Scott Halperin, Jun WangWang